If You Invested $10,000 in Personalis in the Coronavirus Crash, This Is How Much You'd Have Now

If You Invested $10,000 in Personalis in the Coronavirus Crash, This Is How Much You'd Have Now
Taylor Carmichael, The Motley Fool
·5 min read

With so much hype around coronavirus vaccine stocks, it was easy to miss Personalis (NASDAQ: PSNL), which became a 10-bagger after the market crash last year. Personalis is a biotech that competes with Guardant Health (NASDAQ: GH) and Adaptive Biotechnologies (NASDAQ: ADPT) in the cancer genomics space. Other major competitors include NanoString Technologies (NASDAQ: NSTG) and Foundation Medicine, a subsidiary of Roche Holdings (OTC: RHHBY).